Streetbeat News

Products Services

HBI

HanesBrands has renewed its exclusive rights to produce Duke University fanwear for the mass retail channel for another five years, extending their apparel partnership.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:46 pm

AMIX

Autonomix has announced results from a preclinical study indicating that its technology could enhance the safety and effectiveness of renal denervation, a procedure used to treat hypertension. The study's findings support the ongoing development of Autonomix's sensing and ablation technologies, which are moving towards a proof-of-concept clinical study.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:46 pm

B

Barnes Aerospace, a division of Barnes Group Inc., announced plans to expand its Aero Engine Maintenance, Repair, and Overhaul (MRO) facility in East Granby, Connecticut. This expansion aims to enhance the company's capabilities in servicing aero engines, supporting growth in the aerospace sector.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:45 pm

NXL

Nexalin Technology announced an acceleration in the manufacturing of its HALO Clarity units, expecting to produce approximately 500 units in Q3 2024. This move indicates a significant step forward in the company's production capabilities and market readiness for the HALO Clarity product.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:45 pm

AMPX

AIBOT has chosen Amprius Technologies to supply batteries for its aiEVTOL ecosystem, leveraging the superior performance of Amprius's SiCore batteries to enhance range and cost efficiency of aerial vehicles.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:44 pm

LSTA

Lisata Therapeutics has been granted Orphan Drug Designation by the U.S. FDA for its drug LSTA1, aimed at treating osteosarcoma. This designation is significant as it provides various benefits including tax credits, eligibility for market exclusivity, and assistance in the drug development process.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:41 pm

CHRO

Chromocell, under CEO Frank Knuettel II, announced the successful closure of its IPO on February 21, 2024, raising $6.6 million. The company converted all pre-IPO debt and Series A Preferred Stock to common stock and transferred liabilities in exchange for Series C Preferred Stock. Chromocell is focusing on developing non-opioid pain treatments, with its lead compound CC8464 completing Phase I trials and planning for Phase II. Another program, CT2000, targets acute and chronic eye pain. The company aims for fiscal responsibility, leveraging tax credits and exploring non-dilutive capital options.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:40 pm

IMAX

IMAX and Major Cineplex have expanded their partnership by agreeing to open three new IMAX with Laser locations across Thailand. This move is part of IMAX's rapid expansion strategy in Southeast Asia.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:37 pm

IMAX

IMAX and Bona Film Group have expanded their partnership by agreeing to open three new IMAX locations in China. This marks their first agreement since the COVID-19 pandemic, reflecting the continued surge in Chinese moviegoing.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:36 pm

OSIS

OSI Systems has received a $6 million order for its patient monitoring solutions, indicating a positive development for the company and potentially boosting investor confidence in its healthcare technology segment.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:34 pm